NCT00092599已完成3 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 410
- 主要终点
- Percentage of patients reaching LDL goal of <2.60 mmol/L after 6 weeks of treatment
研究概览
简要总结
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
详细描述
The duration of treatment is 10 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with elevated cholesterol and coronary heart disease
排除标准
- •Patients who do not meet specific cholesterol levels as required by the study
结局指标
主要结局
Percentage of patients reaching LDL goal of <2.60 mmol/L after 6 weeks of treatment
次要结局
- Safety and tolerability.
研究者
相似试验
已完成
1 期
BI 409306 Cardiac Safety Trial in Healthy VolunteersHealthyNCT02438683Boehringer Ingelheim12
Unknown
2 期
Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like NanoparticlesInflammationCoronary Artery DiseaseAtherosclerosisNCT04148833University of Sao Paulo General Hospital40
Unknown
2 期
Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like NanoparticlesInflammationAtherosclerosisCoronary Artery DiseaseNCT04616872University of Sao Paulo General Hospital40
已完成
3 期
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease PatientsCoronary Artery Disease (CAD)Coronary AtherosclerosisNCT00853827Novartis Pharmaceuticals613
已完成
4 期
DANHEART (H-HeFT and Met-HeFT)Heart FailureDiabetesNCT03514108Henrik Wiggers1,100